Predict And Verify The Target Gene Of Thalidomide In Hematologic Malignancies

Objective: Predict the signaling pathways,protein-protein interaction(PPI)network and target genes involved in the treatment of hematologic malignancies with thalidomide by using bioinformatics technology.And Verify the target of thalidomide in hematologic malignancies by molecular docking.Methods: The drug information of thalidomide were obtained from Pubchem database and the target genes were extracted from BATMAN-TCM database and Drugbank database.PPI analysis was performed with STRING10.5 database;GO analysis and Pathway analysis of the genes were extracted through WebGestalt database;cBio Portal database and HumanProtein Atlas database were used to analyze the expression and variation of target genes.Schrodinger Suites software was used to verify the target gene.Results: 52 target genes of thalidomide were obtained from BATMAN-TCM database and Drugbank database.The corresponding proteins of 52 target genes were analyzed using STRING10.5 database.A total of 300 interactions with target proteins were screened out;using the Web Gestalt database to carry out pathway analysis of the above gene sets,10 pathways were co-enriched.We screened out the 4 relevant signal pathways for cancer: MAPK signaling pathway?Ras signaling pathway?NF-kappa B signaling pathway?Pathways in cancer;Using the cBioPortal database,the genes acting on the above 4 signal pathways were collected and aggregated to obtain a total of 5 hub genes;5 hub genes were analyzed using The Human Protein Atlas database.CHUK?IKBKB?NFKB1?RELA and IKBKG were found to be highly expressed in lymphoma tissues.Schrodinger Suites software is used to verify that thalidomide is well docked to IKBKB.Conclusion: Thalidomide may play an anti-tumor role in the treatment of hematologic malignancies by regulating CHUK?IKBKB?NFKB1?RELA and IKBKG.IKBKB is a possible target gene for thalidomide.